Imageens, a Paris, France-based medical Artificial Intelligence (AI) startup developing software solutions for the analysis of medical images, raised €1.2M in seed financing.
The round was led by Anaxago, with participation from BADGE (Business Angels des Grandes Ecoles), COALESCENCE, and existing investors.
Led by Robert Baldwin, CEO, Imageens provides software solutions that allow radiologists, cardiologists and vascular surgeons to make personalized decisions and to assess the cardiovascular risk of their patients, thanks to highly accurate medical imaging data.
The company intends to use the funds to accelerate the development and commercialization of ArtFun+, an artificial intelligence software and its prognostic biomarkers for cardiovascular imaging, and LABEL, an algorithmic solution for the automatic classification and valorization of medical imaging data, to strengthen its team with key R&D talents and build its commercial team to scale the deployment of its software solutions.
Today, Imageens is in the process of obtaining FDA and CE-clearance for ArtFun+ in routine cardiovascular care to complement to cardiac MRI exams with cardiovascular risk biomarkers enabling improved follow-up and surgical decisions in ischemic cardiopathies, acute coronary syndrome, and aortic aneurysms.
Since late 2020, the company has also developed a complementary business to its diagnostic solutions, by allowing medical data warehouses to improve the quality of their medical data and use it for R&D and AI-training purposes. By working with medical institutions such as the AP-HP in Paris, Imageens has developed a comprehensive set of image classification algorithms that automatically create metadata allowing the data warehouses to get a detailed understanding of the databases’ content, and the ability to precisely query the medical data to setup cohorts for R&D and AI-training projects.